• English
  • Svenska
  • CLINICAL RESEARCHERS

PRECISION MONITORING IN CANCER CARE

How do cancer patients respond to treatment? TK1 as biomarker in cancer care can help clinicians make timely and decisions about ongoing treatment of every patient.

Read more

BREAST CANCER

Breast cancer is the most common cancer in women worldwide. There is a need for new biomarkers to monitor the effectiveness of treatment. TK1 is a strong candidate.

Read more

HEMATOLOGICAL MALIGNANCIES

TK 210 ELISA offers a simple and cost-effective assay for monitoring of patients under treatment. Preliminary studies show that AroCell TK 210 ELISA can be used to predict outcome and monitor effectiveness of drug treatment DLBCL, the most common non-Hodgkin’s Lymphoma.

Read more

CLINICAL STUDIES

AroCell is participating in several clinical studies, both with partners and independently.

Read more

SO YOU THINK YOU KNOW TK1? - THE UNIQUE BIOMARKER

Increased levels of TK1 in the blood can indicate active cell proliferation as a consequence of abnormal cell turnover and cell disruption triggered by for example drug and therapeutic agents.

Read more

SCIENTIFIC REFERENCES

An extensive list of published articles on applications, Thymidine Kinase 1 and use of AroCell TK 210 ELISA.

Read more

Subscription for news and press releases

We use cookies to improve the user experience and gather anonymous visitor statistics. By using our website, you agree to the use of cookies.

I agree.